Piper Sandler Maintains Overweight on AVITA Medical, Lowers Price Target to $19-Report released on 9th Nov 2023
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on AVITA Medical (NASDAQ:RCEL) but reduced the price target from $23 to $19, as reported on November 9, 2023.

November 10, 2023 | 10:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on AVITA Medical but lowered the price target from $23 to $19.
The reduction in price target by Piper Sandler, despite maintaining an Overweight rating, could lead to a negative perception among investors, potentially causing a short-term dip in RCEL's stock price. The Overweight rating suggests a positive long-term outlook, but the lowered price target indicates a tempered expectation for growth or performance in the near term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100